Welcome to our book review site go-pdf.online!
You may have to Search all our reviewed books and magazines, click the sign up button below to create a free account.
External and Internal Analysis of Glaxo SmithKline
Research Paper (postgraduate) from the year 2012 in the subject Business economics - Business Management, Corporate Governance, grade: A, University of California, Berkeley , language: English, abstract: The common goal of any organization is to achieve its objectives which revolve around profit, survival and prosperity. Robert M. Grant (1991:22) identifies two routes to achieve their objective which includes the location of an industry favorable to earn a rate of return above the competitive level and attain a position of advantage over its competitors within the industry, allowing the company to earn return more than the average return of the industry. Duane Ireland et al (2005) mentioned ...
A Business Deconstructed. Company Analysis of GlaxoSmithKline plc.
Seminar paper from the year 2008 in the subject Business economics - Business Management, Corporate Governance, grade: 1,3, New College Durham, language: English, abstract: GlaxoSmithKline plc. (GSK) was formed in December 2000 by the merger of “Glaxo Wellcome” and “SmithKline Beecham” and is now one of the world’s leading pharmaceutical and healthcare companies. The organisation is headquartered in London and has further production facilities in 114 countries within Europe as well as in Northern America and Asia. Apart from pharmaceutical products and vaccines, health- and sanitary items are also manufactured and sold in over 140 countries. (Annual Report, 2007, p.4) GSK employs o...
GlaxoSmithKline and Access to Essential Medicines (B)
The (B) case summarizes GSK's response to pressures to increase access to essential medicines in developing countries and subsequent developments.
From Financialisation to Innovation in UK Big Pharma
The tension between innovation and financialisation is central to the business corporation. Innovation entails a 'retain-and-reinvest' allocation regime that can form a foundation for stable and equitable economic growth. Driven by shareholder-value ideology, financialisation entails a shift to 'downsize-and-distribute'. This Element investigates this tension in global pharmaceuticals, focusing on the two leading UK companies AstraZeneca and GlaxoSmithKline. In the 2000s both adopted US-style governance, including stock buybacks and stock-based executive pay. Over the past decade, however, first AstraZeneca and then GlaxoSmithKline transitioned to innovation. Critical was the cessation of buybacks to refocus capabilities on investing in an innovative drugs pipeline. Enabling this shift were UK corporate-governance institutions that mitigated US-style shareholder-value maximisation. Reinventing capitalism for the sake of stable and equitable economic growth means eliminating value destruction caused by financialisation and supporting value creation through collective and cumulative innovation. This title is also available as Open Access on Cambridge Core.
GlaxoSmithKline and Developing Country Access to Essential Medicines (A)
The merger of GlaxoWellcome and SmithKlineBeecham in 2000 created the world's second largest pharmaceutical company, GlaxoSmithKline. GSK also became the world's leader in the provision of drugs to treat the three most critical diseases in the developing world: HIV/AIDS, malaria and tuberculosis. In addition to merger related strategy and restructuring activities, the company finds itself having to respond to pressures to increase access to these essential medicines in developing countries, including the possibility of major reductions in price. How should GSK respond to these pressures?
Business strategy and accounting policies of GlaxoSmithKline (GSK)
Essay from the year 2021 in the subject Business economics - Investment and Finance, grade: 1,3, University of Bamberg, language: English, abstract: In order to analyse and interpret the business strategy and the resulting accounting policy choices and disclosures, this paper examines the macroeconomic environment as well as the industrial and firm level of GlaxoSmithKline during the accounting period 2019. Therefore, property, plant and equipment (PPE), intangible assets, business combinations, impairments as well as inventories are considered in more detail. In conclusion, the accounting and disclosure methods are evaluated with regard to their requirements and completeness.
GlaxoSmithKline Plc
None
GlaxoSmithKline
A collection of cuttings from regional and national newspapers.
